data_1u6v_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1u6v _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . 0.411 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 315' ' ' ARG . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.435 ' CG2' ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.435 ' CD1' ' CG2' ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.432 HG22 ' CD2' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.432 ' CD2' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.432 HG22 ' CD2' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.432 ' CD2' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.417 HG21 ' CD2' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.417 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . 0.407 HD12 HG21 ' A' ' 327' ' ' ILE . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.424 HG21 ' CD2' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.424 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.418 HG21 ' CD2' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.438 ' CG2' ' CD2' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.438 ' CD2' ' CG2' ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . 0.405 HG21 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . 0.405 ' CD1' HG21 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . 0.411 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . 0.411 ' CG1' ' HB2' ' A' ' 315' ' ' ARG . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.435 ' CG2' ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.435 ' CD1' ' CG2' ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.432 HG22 ' CD2' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.432 ' CD2' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.432 HG22 ' CD2' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.432 ' CD2' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.417 HG21 ' CD2' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.417 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . 0.407 HD12 HG21 ' A' ' 327' ' ' ILE . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.424 HG21 ' CD2' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.424 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.418 HG21 ' CD2' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.418 ' CD2' HG21 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.438 ' CG2' ' CD2' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.438 ' CD2' ' CG2' ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . 0.405 HG21 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . 0.405 ' CD1' HG21 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.475 HG23 HG22 ' A' ' 326' ' ' THR . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.545 HG22 ' HB3' ' A' ' 324' ' ' PHE . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.545 ' HB3' HG22 ' A' ' 316' ' ' ILE . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.49 ' N ' HG12 ' A' ' 325' ' ' VAL . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.476 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.476 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 313' ' ' SER . . . . . 0.885 ' O ' HD13 ' A' ' 314' ' ' ILE . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.885 HD13 ' O ' ' A' ' 313' ' ' SER . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.42 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.64 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.64 ' HB3' HG22 ' A' ' 316' ' ' ILE . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 326' ' ' THR . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.846 HG22 HG23 ' A' ' 314' ' ' ILE . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.683 HG23 ' HB2' ' A' ' 313' ' ' SER . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.623 HG23 HG22 ' A' ' 326' ' ' THR . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.661 ' HB3' HG13 ' A' ' 325' ' ' VAL . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.627 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.627 ' CD1' HG22 ' A' ' 316' ' ' ILE . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.661 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.623 HG22 HG23 ' A' ' 314' ' ' ILE . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.475 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.475 ' CD1' HG22 ' A' ' 316' ' ' ILE . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.482 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 328' ' ' GLY . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.471 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.83 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.83 ' CD1' HG22 ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 326' ' ' THR . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.493 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.689 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.508 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.461 HG22 ' CD1' ' A' ' 324' ' ' PHE . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.461 ' CD1' HG22 ' A' ' 316' ' ' ILE . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.508 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.689 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.571 ' CG2' HG22 ' A' ' 326' ' ' THR . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.495 HG22 ' HA ' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.495 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.571 HG22 ' CG2' ' A' ' 314' ' ' ILE . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.402 HG22 ' N ' ' A' ' 328' ' ' GLY . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.402 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.961 HG23 HG22 ' A' ' 326' ' ' THR . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.428 ' CB ' HG23 ' A' ' 325' ' ' VAL . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.534 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.534 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.428 HG23 ' CB ' ' A' ' 315' ' ' ARG . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.961 HG22 HG23 ' A' ' 314' ' ' ILE . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.764 HG23 HG22 ' A' ' 326' ' ' THR . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.443 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 326' ' ' THR . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.764 HG22 HG23 ' A' ' 314' ' ' ILE . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.498 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.498 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.991 HG23 HG22 ' A' ' 326' ' ' THR . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.576 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.576 ' CD1' HG22 ' A' ' 316' ' ' ILE . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.991 HG22 HG23 ' A' ' 314' ' ' ILE . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.477 HG22 ' N ' ' A' ' 328' ' ' GLY . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.477 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.67 HG23 HG22 ' A' ' 326' ' ' THR . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.538 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 317' ' ' GLN . . . . . 0.4 ' CB ' ' HG2' ' A' ' 322' ' ' ARG . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 322' ' ' ARG . . . . . 0.4 ' HG2' ' CB ' ' A' ' 317' ' ' GLN . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.538 ' CB ' HG22 ' A' ' 316' ' ' ILE . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.67 HG22 HG23 ' A' ' 314' ' ' ILE . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.872 HG23 HG22 ' A' ' 326' ' ' THR . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.442 ' HB2' HD11 ' A' ' 327' ' ' ILE . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.608 ' CB ' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.872 HG22 HG23 ' A' ' 314' ' ' ILE . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.442 HD11 ' HB2' ' A' ' 315' ' ' ARG . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.441 HG23 ' HB ' ' A' ' 326' ' ' THR . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.581 ' HD3' HD13 ' A' ' 327' ' ' ILE . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.564 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.564 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 326' ' ' THR . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.581 HD13 ' HD3' ' A' ' 315' ' ' ARG . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.437 HG23 ' HB ' ' A' ' 326' ' ' THR . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.792 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.792 ' CD1' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.437 ' HB ' HG23 ' A' ' 314' ' ' ILE . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.415 ' CG2' HG22 ' A' ' 326' ' ' THR . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.465 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.634 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.634 ' HB3' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.415 HG22 ' CG2' ' A' ' 314' ' ' ILE . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.45 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.45 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.463 HG22 ' CA ' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.463 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.496 HG12 ' N ' ' A' ' 326' ' ' THR . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.496 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.543 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.543 ' HB3' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 313' ' ' SER . . . . . 0.776 ' O ' HD13 ' A' ' 314' ' ' ILE . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 313' ' ' SER . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.628 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.628 ' CD1' HG22 ' A' ' 316' ' ' ILE . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 326' ' ' THR . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.461 HG23 ' HB2' ' A' ' 313' ' ' SER . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 315' ' ' ARG . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.415 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.673 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.673 ' HB3' HG22 ' A' ' 316' ' ' ILE . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 326' ' ' THR . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.48 ' N ' HG12 ' A' ' 325' ' ' VAL . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 1.051 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.741 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.567 HG22 ' CG ' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.567 ' CG ' HG22 ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.741 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 326' ' ' THR . . . . . 1.051 HG22 HG23 ' A' ' 314' ' ' ILE . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 328' ' ' GLY . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 328' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.43 HG23 HG22 ' A' ' 326' ' ' THR . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.423 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.412 HG22 ' HB3' ' A' ' 324' ' ' PHE . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 316' ' ' ILE . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.43 HG22 HG23 ' A' ' 314' ' ' ILE . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.458 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 324' ' ' PHE . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.449 ' HA ' HG22 ' A' ' 316' ' ' ILE . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.458 HG22 HG23 ' A' ' 314' ' ' ILE . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.715 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.521 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.521 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.715 HG23 ' HB2' ' A' ' 315' ' ' ARG . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.529 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.529 ' HB3' HG22 ' A' ' 316' ' ' ILE . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 326' ' ' THR . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.486 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.509 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.718 ' CD1' HG22 ' A' ' 316' ' ' ILE . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.582 ' C ' HD12 ' A' ' 327' ' ' ILE . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 326' ' ' THR . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.494 HG12 ' N ' ' A' ' 326' ' ' THR . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 325' ' ' VAL . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 313' ' ' SER . . . . . 0.603 ' C ' HD13 ' A' ' 314' ' ' ILE . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.998 HG23 HG22 ' A' ' 326' ' ' THR . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.722 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 7.7 mp0 -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.722 ' CD1' HG22 ' A' ' 316' ' ' ILE . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 326' ' ' THR . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.998 HG22 HG23 ' A' ' 314' ' ' ILE . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.522 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.522 ' HB3' HG22 ' A' ' 316' ' ' ILE . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 326' ' ' THR . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.483 ' N ' HG12 ' A' ' 325' ' ' VAL . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 327' ' ' ILE . . . . . 0.557 HD12 ' N ' ' A' ' 327' ' ' ILE . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 314' ' ' ILE . . . . . 0.627 HG23 HG22 ' A' ' 326' ' ' THR . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 315' ' ' ARG . . . . . 0.712 ' HB3' HG13 ' A' ' 325' ' ' VAL . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 316' ' ' ILE . . . . . 0.413 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 324' ' ' PHE . . . . . 0.413 ' CD1' HG22 ' A' ' 316' ' ' ILE . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 325' ' ' VAL . . . . . 0.712 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 326' ' ' THR . . . . . 0.627 HG22 HG23 ' A' ' 314' ' ' ILE . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.475 HG23 HG22 ' A' ' 326' ' ' THR . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.545 HG22 ' HB3' ' A' ' 324' ' ' PHE . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.545 ' HB3' HG22 ' A' ' 316' ' ' ILE . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.49 ' N ' HG12 ' A' ' 325' ' ' VAL . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.476 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.476 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 313' ' ' SER . . . . . 0.885 ' O ' HD13 ' A' ' 314' ' ' ILE . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.885 HD13 ' O ' ' A' ' 313' ' ' SER . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.42 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.64 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.64 ' HB3' HG22 ' A' ' 316' ' ' ILE . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 326' ' ' THR . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.846 HG22 HG23 ' A' ' 314' ' ' ILE . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.683 HG23 ' HB2' ' A' ' 313' ' ' SER . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.623 HG23 HG22 ' A' ' 326' ' ' THR . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.661 ' HB3' HG13 ' A' ' 325' ' ' VAL . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.627 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.627 ' CD1' HG22 ' A' ' 316' ' ' ILE . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.661 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.623 HG22 HG23 ' A' ' 314' ' ' ILE . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.475 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.475 ' CD1' HG22 ' A' ' 316' ' ' ILE . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.482 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 328' ' ' GLY . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.471 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.83 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.83 ' CD1' HG22 ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 326' ' ' THR . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.493 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.689 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.508 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.461 HG22 ' CD1' ' A' ' 324' ' ' PHE . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.461 ' CD1' HG22 ' A' ' 316' ' ' ILE . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.508 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.689 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.571 ' CG2' HG22 ' A' ' 326' ' ' THR . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.495 HG22 ' HA ' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.495 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.571 HG22 ' CG2' ' A' ' 314' ' ' ILE . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.402 HG22 ' N ' ' A' ' 328' ' ' GLY . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.402 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.961 HG23 HG22 ' A' ' 326' ' ' THR . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.428 ' CB ' HG23 ' A' ' 325' ' ' VAL . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.534 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.534 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.428 HG23 ' CB ' ' A' ' 315' ' ' ARG . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.961 HG22 HG23 ' A' ' 314' ' ' ILE . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.764 HG23 HG22 ' A' ' 326' ' ' THR . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.443 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 326' ' ' THR . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.764 HG22 HG23 ' A' ' 314' ' ' ILE . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.498 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.498 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.991 HG23 HG22 ' A' ' 326' ' ' THR . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.576 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.576 ' CD1' HG22 ' A' ' 316' ' ' ILE . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.991 HG22 HG23 ' A' ' 314' ' ' ILE . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.477 HG22 ' N ' ' A' ' 328' ' ' GLY . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.477 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.67 HG23 HG22 ' A' ' 326' ' ' THR . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.538 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 317' ' ' GLN . . . . . 0.4 ' CB ' ' HG2' ' A' ' 322' ' ' ARG . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 322' ' ' ARG . . . . . 0.4 ' HG2' ' CB ' ' A' ' 317' ' ' GLN . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.538 ' CB ' HG22 ' A' ' 316' ' ' ILE . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.67 HG22 HG23 ' A' ' 314' ' ' ILE . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.872 HG23 HG22 ' A' ' 326' ' ' THR . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.442 ' HB2' HD11 ' A' ' 327' ' ' ILE . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.608 ' CB ' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.872 HG22 HG23 ' A' ' 314' ' ' ILE . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.442 HD11 ' HB2' ' A' ' 315' ' ' ARG . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.441 HG23 ' HB ' ' A' ' 326' ' ' THR . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.581 ' HD3' HD13 ' A' ' 327' ' ' ILE . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.564 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.564 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 326' ' ' THR . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.581 HD13 ' HD3' ' A' ' 315' ' ' ARG . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.437 HG23 ' HB ' ' A' ' 326' ' ' THR . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.792 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 5.0 mp0 -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.792 ' CD1' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.437 ' HB ' HG23 ' A' ' 314' ' ' ILE . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.415 ' CG2' HG22 ' A' ' 326' ' ' THR . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.465 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.634 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.634 ' HB3' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.415 HG22 ' CG2' ' A' ' 314' ' ' ILE . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.45 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.45 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.463 HG22 ' CA ' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.463 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.496 HG12 ' N ' ' A' ' 326' ' ' THR . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.496 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.543 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.543 ' HB3' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 313' ' ' SER . . . . . 0.776 ' O ' HD13 ' A' ' 314' ' ' ILE . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 313' ' ' SER . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.628 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.628 ' CD1' HG22 ' A' ' 316' ' ' ILE . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 326' ' ' THR . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.461 HG23 ' HB2' ' A' ' 313' ' ' SER . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 315' ' ' ARG . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.415 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.673 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.673 ' HB3' HG22 ' A' ' 316' ' ' ILE . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 326' ' ' THR . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.48 ' N ' HG12 ' A' ' 325' ' ' VAL . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 1.051 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.741 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.567 HG22 ' CG ' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.567 ' CG ' HG22 ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.741 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 326' ' ' THR . . . . . 1.051 HG22 HG23 ' A' ' 314' ' ' ILE . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 328' ' ' GLY . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 328' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.43 HG23 HG22 ' A' ' 326' ' ' THR . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.423 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.412 HG22 ' HB3' ' A' ' 324' ' ' PHE . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 316' ' ' ILE . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.43 HG22 HG23 ' A' ' 314' ' ' ILE . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.458 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 324' ' ' PHE . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.449 ' HA ' HG22 ' A' ' 316' ' ' ILE . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.458 HG22 HG23 ' A' ' 314' ' ' ILE . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.715 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.521 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.521 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.715 HG23 ' HB2' ' A' ' 315' ' ' ARG . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.529 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.529 ' HB3' HG22 ' A' ' 316' ' ' ILE . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 326' ' ' THR . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.486 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.509 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.718 ' CD1' HG22 ' A' ' 316' ' ' ILE . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.582 ' C ' HD12 ' A' ' 327' ' ' ILE . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 326' ' ' THR . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.494 HG12 ' N ' ' A' ' 326' ' ' THR . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 325' ' ' VAL . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 313' ' ' SER . . . . . 0.603 ' C ' HD13 ' A' ' 314' ' ' ILE . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.998 HG23 HG22 ' A' ' 326' ' ' THR . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.722 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 7.7 mp0 -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.722 ' CD1' HG22 ' A' ' 316' ' ' ILE . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 326' ' ' THR . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.998 HG22 HG23 ' A' ' 314' ' ' ILE . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.522 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.522 ' HB3' HG22 ' A' ' 316' ' ' ILE . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 326' ' ' THR . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.483 ' N ' HG12 ' A' ' 325' ' ' VAL . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 327' ' ' ILE . . . . . 0.557 HD12 ' N ' ' A' ' 327' ' ' ILE . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 314' ' ' ILE . . . . . 0.627 HG23 HG22 ' A' ' 326' ' ' THR . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 315' ' ' ARG . . . . . 0.712 ' HB3' HG13 ' A' ' 325' ' ' VAL . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 316' ' ' ILE . . . . . 0.413 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 324' ' ' PHE . . . . . 0.413 ' CD1' HG22 ' A' ' 316' ' ' ILE . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 325' ' ' VAL . . . . . 0.712 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 326' ' ' THR . . . . . 0.627 HG22 HG23 ' A' ' 314' ' ' ILE . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.475 HG23 HG22 ' A' ' 326' ' ' THR . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.545 HG22 ' HB3' ' A' ' 324' ' ' PHE . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.545 ' HB3' HG22 ' A' ' 316' ' ' ILE . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.49 ' N ' HG12 ' A' ' 325' ' ' VAL . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.476 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.476 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . 0.885 ' O ' HD13 ' A' ' 314' ' ' ILE . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.885 HD13 ' O ' ' A' ' 313' ' ' SER . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.42 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.64 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.64 ' HB3' HG22 ' A' ' 316' ' ' ILE . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 326' ' ' THR . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.846 HG22 HG23 ' A' ' 314' ' ' ILE . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.683 HG23 ' HB2' ' A' ' 313' ' ' SER . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.623 HG23 HG22 ' A' ' 326' ' ' THR . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.661 ' HB3' HG13 ' A' ' 325' ' ' VAL . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.627 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.627 ' CD1' HG22 ' A' ' 316' ' ' ILE . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.661 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.623 HG22 HG23 ' A' ' 314' ' ' ILE . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.475 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.475 ' CD1' HG22 ' A' ' 316' ' ' ILE . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.482 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 328' ' ' GLY . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.471 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.83 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.83 ' CD1' HG22 ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 326' ' ' THR . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.493 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.689 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.508 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.461 HG22 ' CD1' ' A' ' 324' ' ' PHE . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.461 ' CD1' HG22 ' A' ' 316' ' ' ILE . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.508 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.689 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.571 ' CG2' HG22 ' A' ' 326' ' ' THR . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.495 HG22 ' HA ' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.495 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.571 HG22 ' CG2' ' A' ' 314' ' ' ILE . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.402 HG22 ' N ' ' A' ' 328' ' ' GLY . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.402 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.961 HG23 HG22 ' A' ' 326' ' ' THR . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.428 ' CB ' HG23 ' A' ' 325' ' ' VAL . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.534 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.534 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.428 HG23 ' CB ' ' A' ' 315' ' ' ARG . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.961 HG22 HG23 ' A' ' 314' ' ' ILE . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.764 HG23 HG22 ' A' ' 326' ' ' THR . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.443 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 326' ' ' THR . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.764 HG22 HG23 ' A' ' 314' ' ' ILE . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.498 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.498 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.991 HG23 HG22 ' A' ' 326' ' ' THR . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.576 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.576 ' CD1' HG22 ' A' ' 316' ' ' ILE . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.991 HG22 HG23 ' A' ' 314' ' ' ILE . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.477 HG22 ' N ' ' A' ' 328' ' ' GLY . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.477 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.67 HG23 HG22 ' A' ' 326' ' ' THR . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.538 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . 0.4 ' CB ' ' HG2' ' A' ' 322' ' ' ARG . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . 0.4 ' HG2' ' CB ' ' A' ' 317' ' ' GLN . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.538 ' CB ' HG22 ' A' ' 316' ' ' ILE . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.67 HG22 HG23 ' A' ' 314' ' ' ILE . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.872 HG23 HG22 ' A' ' 326' ' ' THR . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.442 ' HB2' HD11 ' A' ' 327' ' ' ILE . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.608 ' CB ' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.872 HG22 HG23 ' A' ' 314' ' ' ILE . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.442 HD11 ' HB2' ' A' ' 315' ' ' ARG . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.441 HG23 ' HB ' ' A' ' 326' ' ' THR . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.581 ' HD3' HD13 ' A' ' 327' ' ' ILE . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.564 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.564 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 326' ' ' THR . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.581 HD13 ' HD3' ' A' ' 315' ' ' ARG . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.437 HG23 ' HB ' ' A' ' 326' ' ' THR . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.792 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.792 ' CD1' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.437 ' HB ' HG23 ' A' ' 314' ' ' ILE . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.415 ' CG2' HG22 ' A' ' 326' ' ' THR . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.465 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.634 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.634 ' HB3' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.415 HG22 ' CG2' ' A' ' 314' ' ' ILE . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.45 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.45 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.463 HG22 ' CA ' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.463 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.496 HG12 ' N ' ' A' ' 326' ' ' THR . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.496 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.543 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.543 ' HB3' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . 0.776 ' O ' HD13 ' A' ' 314' ' ' ILE . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 313' ' ' SER . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.628 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.628 ' CD1' HG22 ' A' ' 316' ' ' ILE . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 326' ' ' THR . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.461 HG23 ' HB2' ' A' ' 313' ' ' SER . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 315' ' ' ARG . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.415 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.673 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.673 ' HB3' HG22 ' A' ' 316' ' ' ILE . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 326' ' ' THR . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.48 ' N ' HG12 ' A' ' 325' ' ' VAL . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 1.051 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.741 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.567 HG22 ' CG ' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.567 ' CG ' HG22 ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.741 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 1.051 HG22 HG23 ' A' ' 314' ' ' ILE . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 328' ' ' GLY . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.43 HG23 HG22 ' A' ' 326' ' ' THR . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.423 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.412 HG22 ' HB3' ' A' ' 324' ' ' PHE . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 316' ' ' ILE . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.43 HG22 HG23 ' A' ' 314' ' ' ILE . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.458 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 324' ' ' PHE . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.449 ' HA ' HG22 ' A' ' 316' ' ' ILE . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.458 HG22 HG23 ' A' ' 314' ' ' ILE . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.715 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.521 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.521 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.715 HG23 ' HB2' ' A' ' 315' ' ' ARG . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.529 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.529 ' HB3' HG22 ' A' ' 316' ' ' ILE . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 326' ' ' THR . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.486 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.509 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.718 ' CD1' HG22 ' A' ' 316' ' ' ILE . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.582 ' C ' HD12 ' A' ' 327' ' ' ILE . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 326' ' ' THR . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.494 HG12 ' N ' ' A' ' 326' ' ' THR . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 325' ' ' VAL . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . 0.603 ' C ' HD13 ' A' ' 314' ' ' ILE . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.998 HG23 HG22 ' A' ' 326' ' ' THR . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.722 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.722 ' CD1' HG22 ' A' ' 316' ' ' ILE . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 326' ' ' THR . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.998 HG22 HG23 ' A' ' 314' ' ' ILE . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.522 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.522 ' HB3' HG22 ' A' ' 316' ' ' ILE . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 326' ' ' THR . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.483 ' N ' HG12 ' A' ' 325' ' ' VAL . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . 0.557 ' N ' HD12 ' A' ' 327' ' ' ILE . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 314' ' ' ILE . . . . . 0.627 HG23 HG22 ' A' ' 326' ' ' THR . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 315' ' ' ARG . . . . . 0.712 ' HB3' HG13 ' A' ' 325' ' ' VAL . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 316' ' ' ILE . . . . . 0.413 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 324' ' ' PHE . . . . . 0.413 ' CD1' HG22 ' A' ' 316' ' ' ILE . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 325' ' ' VAL . . . . . 0.712 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 326' ' ' THR . . . . . 0.627 HG22 HG23 ' A' ' 314' ' ' ILE . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 51.2 mmtt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.965 0.412 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -149.39 104.98 3.43 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.64 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.475 HG23 HG22 ' A' ' 326' ' ' THR . 3.8 mm -93.65 160.07 2.73 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.123 0.487 . . . . 0.0 111.465 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 17.7 tpp180 -139.49 79.63 1.73 Allowed 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.672 -0.695 . . . . 0.0 109.81 178.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.545 HG22 ' HB3' ' A' ' 324' ' ' PHE . 1.3 pt -109.86 132.68 57.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.399 -179.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.9 tt0 -115.76 149.43 38.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.955 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -120.74 153.73 36.59 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.711 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 116.88 161.06 12.13 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.488 -179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.22 130.51 35.77 Favored 'Trans proline' 0 C--N 1.344 0.337 0 C-N-CA 122.58 2.186 . . . . 0.0 112.38 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 70.07 25.56 75.44 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.683 179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.6 mmt-85 -108.24 137.78 45.63 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.79 0.328 . . . . 0.0 110.773 179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -109.25 169.75 8.49 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.16 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.545 ' HB3' HG22 ' A' ' 316' ' ' ILE . 32.5 m-85 -114.52 139.33 49.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.863 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 18.1 t -138.54 159.81 31.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.066 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.49 ' N ' HG12 ' A' ' 325' ' ' VAL . 11.4 p -147.72 139.98 24.39 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.947 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.476 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.5 mp -134.16 158.44 42.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.098 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.476 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.466 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.9 mmtm . . . . . 0 C--O 1.23 0.074 0 CA-C-O 120.914 0.388 . . . . 0.0 111.048 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . 0.885 ' O ' HD13 ' A' ' 314' ' ' ILE . 3.8 m -142.12 128.53 20.05 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.646 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.885 HD13 ' O ' ' A' ' 313' ' ' SER . 4.1 mm -137.15 160.16 36.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.124 0.488 . . . . 0.0 111.491 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.42 ' HB2' ' CG1' ' A' ' 325' ' ' VAL . 48.1 mmm-85 -140.33 79.97 1.73 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.893 179.037 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.64 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.7 pt -116.99 111.66 36.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.238 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -124.68 139.5 53.8 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.869 -179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.76 136.57 32.96 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.928 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.14 171.11 37.51 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.846 -0.693 . . . . 0.0 112.384 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_endo -60.45 93.2 0.1 OUTLIER 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 122.6 2.2 . . . . 0.0 112.173 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 81.51 40.75 10.64 Favored Glycine 0 N--CA 1.45 -0.404 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.462 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 5.2 mmp_? -89.92 132.67 35.19 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.848 0.356 . . . . 0.0 111.045 -179.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.73 170.08 10.74 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.224 -179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.64 ' HB3' HG22 ' A' ' 316' ' ' ILE . 23.5 m-85 -133.05 121.44 22.71 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.976 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.442 HG22 ' N ' ' A' ' 326' ' ' THR . 11.8 p -127.58 156.63 39.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.003 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.846 HG22 HG23 ' A' ' 314' ' ' ILE . 10.5 p -140.41 141.88 35.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.938 0.399 . . . . 0.0 111.12 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.683 HG23 ' HB2' ' A' ' 313' ' ' SER . 7.1 tt -133.78 151.05 32.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.902 179.843 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.285 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.562 179.972 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 68.2 mmtt . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.851 0.358 . . . . 0.0 110.905 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -150.06 103.54 3.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.777 179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.623 HG23 HG22 ' A' ' 326' ' ' THR . 2.1 mm -96.92 160.17 2.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.194 -179.967 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.661 ' HB3' HG13 ' A' ' 325' ' ' VAL . 16.4 tpp85 -135.33 79.91 1.81 Allowed 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.3 179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.627 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.8 pt -121.08 119.27 58.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.404 -179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.3 pp0? -134.84 148.55 50.17 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.767 179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -89.93 -177.0 5.1 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.113 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 117.0 148.16 8.78 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.896 -0.669 . . . . 0.0 112.447 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -49.68 118.72 3.98 Favored 'Trans proline' 0 C--N 1.346 0.441 0 C-N-CA 122.481 2.121 . . . . 0.0 112.236 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 76.91 33.63 45.36 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.629 -0.796 . . . . 0.0 112.278 -179.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.78 143.55 26.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.926 0.394 . . . . 0.0 111.05 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -119.68 145.39 46.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.004 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.627 ' CD1' HG22 ' A' ' 316' ' ' ILE . 40.1 m-85 -103.06 135.47 44.68 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.985 -179.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.661 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.1 p -150.02 129.66 3.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.067 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.623 HG22 HG23 ' A' ' 314' ' ' ILE . 17.3 p -108.39 149.0 29.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.004 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -139.92 147.7 23.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.094 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.368 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.476 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 12.4 mmtt . . . . . 0 C--O 1.231 0.112 0 CA-C-O 120.846 0.355 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 22.7 t -134.21 102.8 5.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.751 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.9 mm -98.83 160.18 3.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.237 -179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 4.2 tpp85 -134.26 79.79 1.83 Allowed 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.325 179.305 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.475 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -114.76 115.81 50.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 115.982 -0.553 . . . . 0.0 111.417 -179.606 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.7 pm0 -147.07 149.81 33.8 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.834 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.99 169.4 9.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.957 -179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.89 142.87 3.91 Favored Glycine 0 CA--C 1.52 0.347 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.407 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -53.31 93.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.373 2.049 . . . . 0.0 112.286 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 105.78 31.67 4.12 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.791 -0.718 . . . . 0.0 112.427 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.6 mmt-85 -121.14 159.16 26.39 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.832 0.348 . . . . 0.0 110.865 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -134.49 170.03 16.38 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.09 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.475 ' CD1' HG22 ' A' ' 316' ' ' ILE . 62.6 m-85 -99.64 138.3 36.92 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.901 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -138.41 159.8 31.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.005 -179.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.482 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.7 OUTLIER -143.54 151.28 40.05 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.047 179.978 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.471 HG22 ' N ' ' A' ' 328' ' ' GLY . 21.6 mt -150.02 159.14 5.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.054 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.471 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.392 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.532 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 16.7 mmmt . . . . . 0 C--O 1.231 0.098 0 CA-C-O 120.901 0.381 . . . . 0.0 110.995 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 p -142.1 109.23 5.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.764 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.1 mm -101.8 160.16 4.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.305 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.44 79.7 1.78 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.159 179.237 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.83 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -114.89 127.43 72.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.072 -0.513 . . . . 0.0 111.331 -179.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -135.46 154.76 51.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.832 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 12.3 ptt180 -119.24 133.52 55.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.959 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.0 167.46 11.87 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.453 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -54.32 104.27 0.11 Allowed 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.547 2.165 . . . . 0.0 112.377 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 92.93 33.31 7.42 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.587 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 6.5 mpt_? -122.76 117.15 25.03 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.827 0.346 . . . . 0.0 110.995 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -110.2 169.97 8.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.83 ' CD1' HG22 ' A' ' 316' ' ' ILE . 23.7 m-85 -99.2 138.64 36.01 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 326' ' ' THR . 13.7 t -146.53 161.3 9.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.038 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.493 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.1 t -143.24 153.2 42.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.022 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.8 mp -141.64 143.84 26.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.562 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.792 0.329 . . . . 0.0 111.067 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 3.9 m -150.01 101.92 3.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.805 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.689 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.5 mm -96.83 160.2 2.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.258 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.508 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.3 mtp180 -136.7 79.71 1.77 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.209 179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.461 HG22 ' CD1' ' A' ' 324' ' ' PHE . 3.1 pt -117.53 124.15 72.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.94 -0.573 . . . . 0.0 111.35 -179.562 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -120.45 156.85 30.59 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.755 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.01 167.96 12.37 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.963 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 125.49 149.94 7.61 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.458 -179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -63.76 -26.46 68.12 Favored 'Trans proline' 0 C--N 1.344 0.313 0 C-N-CA 122.573 2.182 . . . . 0.0 112.28 179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -116.47 27.67 7.9 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.5 179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -101.96 136.61 41.5 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.81 0.338 . . . . 0.0 110.919 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.39 169.97 9.83 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.046 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.461 ' CD1' HG22 ' A' ' 316' ' ' ILE . 46.9 m-85 -125.85 109.89 13.04 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.878 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.508 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.35 167.6 13.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.067 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.689 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.6 OUTLIER -150.14 150.51 31.76 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.067 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 2.2 mp -134.02 142.33 41.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.963 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.267 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.574 -179.954 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.9 mmtp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.89 0.376 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.7 p -144.76 104.83 4.06 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.849 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.571 ' CG2' HG22 ' A' ' 326' ' ' THR . 1.6 mm -97.41 159.08 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.218 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 52.7 mmm-85 -135.86 79.84 1.8 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.172 179.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.495 HG22 ' HA ' ' A' ' 324' ' ' PHE . 9.6 pt -124.7 119.04 55.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.976 -0.556 . . . . 0.0 111.364 -179.441 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.12 151.13 39.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.841 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 169.03 11.02 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.938 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 136.7 157.29 7.66 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.509 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.34 98.16 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.586 2.191 . . . . 0.0 112.23 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 97.73 27.01 9.31 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.05 155.1 18.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.826 0.346 . . . . 0.0 110.895 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.91 154.59 24.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.124 -179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.495 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -103.89 109.99 21.94 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.845 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 9.8 t -108.62 146.89 13.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.998 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.571 HG22 ' CG2' ' A' ' 314' ' ' ILE . 17.7 p -140.57 138.88 34.8 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.997 179.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.402 HG22 ' N ' ' A' ' 328' ' ' GLY . 29.4 mt -136.88 153.92 30.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.143 -0.48 . . . . 0.0 111.107 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.402 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.301 0 C-N-CA 120.677 -0.773 . . . . 0.0 112.531 -179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.8 0.333 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.5 t -149.02 113.66 5.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.798 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.961 HG23 HG22 ' A' ' 326' ' ' THR . 2.4 mm -99.76 160.29 3.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.095 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.428 ' CB ' HG23 ' A' ' 325' ' ' VAL . 0.0 OUTLIER -133.55 79.89 1.85 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.416 179.362 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.534 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.1 pt -115.17 113.13 42.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.265 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -134.61 158.27 44.46 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.702 -179.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.84 171.49 9.1 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.49 144.61 4.21 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.497 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -53.69 92.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.59 2.193 . . . . 0.0 112.234 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.98 43.02 5.17 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.506 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.12 154.75 17.16 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.791 0.329 . . . . 0.0 110.809 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.36 153.71 30.52 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.534 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.9 m-85 -106.05 112.36 25.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.843 -179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.428 HG23 ' CB ' ' A' ' 315' ' ' ARG . 3.4 m -113.14 168.92 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.183 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.961 HG22 HG23 ' A' ' 314' ' ' ILE . 75.9 p -140.92 137.1 32.89 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.8 mt -119.43 152.51 21.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.337 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.525 -179.976 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 8.8 mmtp . . . . . 0 C--O 1.232 0.137 0 CA-C-O 120.857 0.361 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -141.93 101.87 4.03 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.769 179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.764 HG23 HG22 ' A' ' 326' ' ' THR . 3.4 mm -99.9 160.28 3.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.192 -179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 22.0 mmm-85 -137.26 79.91 1.78 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.289 179.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.443 HG22 ' HA ' ' A' ' 324' ' ' PHE . 11.7 pt -126.03 129.96 72.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.356 -179.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.52 147.26 27.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.819 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.0 ptt85 -96.31 131.35 42.92 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.999 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 173.04 173.27 39.33 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.48 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -67.01 95.21 0.35 Allowed 'Trans proline' 0 C--N 1.345 0.366 0 C-N-CA 122.474 2.116 . . . . 0.0 112.266 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.03 28.2 9.53 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.502 -179.966 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 7.0 mmp_? -95.54 138.91 32.56 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.788 0.328 . . . . 0.0 110.982 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -112.94 152.89 28.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.126 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.443 ' HA ' HG22 ' A' ' 316' ' ' ILE . 3.5 m-85 -106.21 111.58 24.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.862 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.491 HG22 ' N ' ' A' ' 326' ' ' THR . 12.1 p -128.75 159.1 40.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.149 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.764 HG22 HG23 ' A' ' 314' ' ' ILE . 23.7 p -137.35 138.52 40.03 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.914 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 23.3 mt -132.14 150.68 33.87 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.121 179.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.473 -179.926 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmmt . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.832 0.348 . . . . 0.0 110.909 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.9 m -132.42 107.97 8.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.846 179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.9 mm -98.78 160.27 3.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.283 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -137.35 79.85 1.77 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.29 179.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.498 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.9 pt -125.18 133.56 69.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.339 -179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -135.31 151.43 50.53 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.787 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.67 128.34 56.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.876 179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 165.05 179.56 39.06 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.533 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 93.58 0.37 Allowed 'Trans proline' 0 C--N 1.343 0.25 0 C-N-CA 122.649 2.233 . . . . 0.0 112.177 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 98.7 27.4 8.48 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.403 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -103.85 127.12 51.37 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.807 0.336 . . . . 0.0 110.956 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -101.68 165.15 11.37 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.001 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.498 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.3 m-85 -104.63 116.92 32.89 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.851 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.4 t -126.13 160.0 33.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.129 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 4.1 t -141.69 162.13 36.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.919 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 27.9 mt -146.87 146.55 18.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.179 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.292 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.514 179.935 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 14.4 mmtp . . . . . 0 C--O 1.231 0.085 0 CA-C-O 120.848 0.356 . . . . 0.0 110.976 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -143.88 109.89 5.34 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.735 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.991 HG23 HG22 ' A' ' 326' ' ' THR . 2.5 mm -95.98 160.14 2.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 121.104 0.478 . . . . 0.0 111.383 -179.815 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.78 79.84 1.8 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.045 179.037 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.576 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.0 OUTLIER -106.21 110.33 31.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.341 -179.528 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -117.89 159.95 22.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.759 179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 9.2 ptt180 -105.32 156.67 17.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.08 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.6 145.07 4.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.466 179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_exo -52.21 -25.99 25.24 Favored 'Trans proline' 0 C--N 1.345 0.346 0 C-N-CA 122.495 2.13 . . . . 0.0 112.302 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -129.54 27.4 4.18 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.556 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.0 mmt85 -98.5 144.64 27.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.772 0.32 . . . . 0.0 110.915 179.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -114.31 170.05 8.58 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.279 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.576 ' CD1' HG22 ' A' ' 316' ' ' ILE . 34.6 m-85 -110.5 109.93 20.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.811 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.3 m -114.18 126.73 71.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.228 -179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.991 HG22 HG23 ' A' ' 314' ' ' ILE . 55.2 p -101.4 134.93 43.73 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.935 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.477 HG22 ' N ' ' A' ' 328' ' ' GLY . 4.1 mp -119.12 158.5 20.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.143 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.477 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.327 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.454 -179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.1 mmtt . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.839 0.352 . . . . 0.0 110.997 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.03 107.28 3.6 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.717 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.67 HG23 HG22 ' A' ' 326' ' ' THR . 2.9 mm -98.46 160.03 3.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.011 0.434 . . . . 0.0 111.335 179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 5.4 tpm_? -138.81 79.71 1.75 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.986 179.177 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.538 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.5 pt -120.99 140.95 43.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 115.96 -0.564 . . . . 0.0 111.434 -179.241 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . 0.4 ' CB ' ' HG2' ' A' ' 322' ' ' ARG . 0.6 OUTLIER -139.76 145.93 38.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.817 179.858 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 14.2 mtm180 -93.17 148.23 22.2 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.015 -179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 144.77 159.75 8.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.551 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_exo -51.99 -58.77 1.38 Allowed 'Trans proline' 0 C--N 1.345 0.365 0 C-N-CA 122.619 2.213 . . . . 0.0 112.348 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -95.01 38.9 2.99 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.516 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . 0.4 ' HG2' ' CB ' ' A' ' 317' ' ' GLN . 0.0 OUTLIER -109.33 143.08 39.33 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 110.829 -179.964 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -116.17 170.04 8.82 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.167 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.538 ' CB ' HG22 ' A' ' 316' ' ' ILE . 29.9 m-85 -123.65 109.96 14.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.92 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 1.3 m -129.1 119.88 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.094 179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.67 HG22 HG23 ' A' ' 314' ' ' ILE . 20.3 p -96.58 153.19 17.99 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.046 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 19.8 mt -135.06 147.43 29.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.065 179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.359 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.499 -179.987 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 7.5 mmtp . . . . . 0 C--O 1.233 0.19 0 CA-C-O 120.842 0.353 . . . . 0.0 110.848 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 93.6 p -150.11 111.92 4.54 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.699 179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.872 HG23 HG22 ' A' ' 326' ' ' THR . 3.9 mm -97.91 160.16 3.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.029 0.442 . . . . 0.0 111.412 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.442 ' HB2' HD11 ' A' ' 327' ' ' ILE . 0.1 OUTLIER -139.5 79.74 1.74 Allowed 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.978 179.009 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.608 HG22 ' CB ' ' A' ' 324' ' ' PHE . 3.1 pt -115.67 129.65 71.63 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.78 -0.646 . . . . 0.0 111.395 -179.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -123.83 128.48 49.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.749 179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -89.96 169.18 11.43 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.951 -179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 106.79 142.71 10.82 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.429 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.2 Cg_exo -52.97 106.28 0.15 Allowed 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.496 2.131 . . . . 0.0 112.25 -179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 120.83 -21.37 8.43 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.802 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 32.6 mmt-85 -89.85 138.7 31.26 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.867 0.365 . . . . 0.0 110.943 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -106.56 169.89 8.25 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.092 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.608 ' CB ' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -105.64 125.78 51.39 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.874 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 29.7 t -126.6 153.82 35.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.998 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.872 HG22 HG23 ' A' ' 314' ' ' ILE . 70.7 p -139.8 139.14 36.32 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.0 179.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.442 HD11 ' HB2' ' A' ' 315' ' ' ARG . 3.0 mp -127.22 130.26 70.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.988 179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.389 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.534 179.992 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.8 mmtt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.755 0.312 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 67.7 m -143.66 104.05 4.15 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.736 179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.441 HG23 ' HB ' ' A' ' 326' ' ' THR . 3.3 mm -92.9 160.22 2.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.095 0.474 . . . . 0.0 111.319 -179.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.581 ' HD3' HD13 ' A' ' 327' ' ' ILE . 1.4 mpt_? -139.44 79.81 1.74 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.059 179.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.564 HG22 ' CA ' ' A' ' 324' ' ' PHE . 10.7 pt -125.21 143.07 40.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.371 -179.307 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.1 mp0 -143.88 147.04 33.47 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 30.5 mtm180 -108.59 137.89 45.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.999 179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 174.6 16.11 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.558 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -64.94 109.01 1.2 Allowed 'Trans proline' 0 C--N 1.345 0.352 0 C-N-CA 122.592 2.195 . . . . 0.0 112.228 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 90.62 24.47 28.12 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.508 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 23.1 mmt85 -108.09 129.78 55.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 0.0 110.898 -179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.54 158.02 17.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.039 180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.564 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.7 m-85 -102.9 110.26 22.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.848 179.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.489 HG12 ' N ' ' A' ' 326' ' ' THR . 18.5 t -121.55 159.63 23.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.103 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.489 ' N ' HG12 ' A' ' 325' ' ' VAL . 0.6 OUTLIER -144.81 151.24 38.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.967 179.89 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.581 HD13 ' HD3' ' A' ' 315' ' ' ARG . 4.0 mp -142.78 147.14 21.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.114 179.954 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.398 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.522 179.951 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 111.086 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.1 t -149.96 99.95 2.89 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.69 179.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.437 HG23 ' HB ' ' A' ' 326' ' ' THR . 1.8 mm -100.75 160.04 3.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-O 121.118 0.485 . . . . 0.0 111.394 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.67 79.7 1.76 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.944 179.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.792 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.4 pt -110.52 122.93 65.91 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.398 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -132.15 160.04 37.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.806 179.884 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.9 mtm180 -115.28 156.47 25.36 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.919 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.55 171.99 14.14 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.543 179.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -66.39 108.92 1.47 Allowed 'Trans proline' 0 C--N 1.344 0.29 0 C-N-CA 122.529 2.152 . . . . 0.0 112.266 179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 83.47 25.47 47.01 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.538 -179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -95.98 134.91 38.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.842 0.353 . . . . 0.0 110.881 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.5 169.29 8.91 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.123 179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.792 ' CD1' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -110.1 109.95 20.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.843 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 4.9 m -112.72 119.0 59.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.123 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.437 ' HB ' HG23 ' A' ' 314' ' ' ILE . 1.1 t -105.75 154.33 20.64 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.071 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.6 mp -140.86 142.92 29.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.073 179.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.473 179.974 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.116 0 CA-C-O 120.833 0.349 . . . . 0.0 110.96 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -138.19 115.98 11.49 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.758 179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.415 ' CG2' HG22 ' A' ' 326' ' ' THR . 3.7 mm -102.42 160.13 4.24 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-O 121.047 0.451 . . . . 0.0 111.361 -179.846 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.465 ' HB2' HG23 ' A' ' 325' ' ' VAL . 3.7 mmt85 -139.34 79.63 1.73 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.942 178.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.634 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.6 pt -112.87 126.83 70.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.795 -0.639 . . . . 0.0 111.466 -179.313 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.68 126.68 22.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.593 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -102.49 135.86 43.36 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.343 -0.39 . . . . 0.0 110.963 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 167.76 -177.19 42.2 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.353 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 41.6 Cg_endo -67.65 93.15 0.37 Allowed 'Trans proline' 0 C--N 1.345 0.392 0 C-N-CA 122.586 2.191 . . . . 0.0 112.264 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.66 27.58 10.37 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.494 179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -104.08 155.32 18.79 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.822 0.344 . . . . 0.0 110.959 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -123.55 170.0 10.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.079 179.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.634 ' HB3' HG22 ' A' ' 316' ' ' ILE . 22.9 m-85 -122.45 109.89 14.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.989 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.465 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.9 m -120.08 167.26 13.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.128 179.919 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.415 HG22 ' CG2' ' A' ' 314' ' ' ILE . 7.0 p -148.69 140.7 23.88 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.976 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.45 HG22 ' N ' ' A' ' 328' ' ' GLY . 3.6 mp -135.8 157.26 38.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.999 179.932 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.45 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.547 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.9 mmtt . . . . . 0 C--O 1.231 0.095 0 CA-C-O 120.847 0.356 . . . . 0.0 110.875 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -147.56 117.3 7.12 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.749 179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.9 mm -105.32 160.12 5.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.281 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -138.45 79.76 1.75 Allowed 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.835 -0.62 . . . . 0.0 110.166 179.166 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.463 HG22 ' CA ' ' A' ' 324' ' ' PHE . 7.4 pt -122.42 137.16 56.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.36 0 CA-C-N 115.868 -0.605 . . . . 0.0 111.394 -179.364 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.0 mt-30 -134.6 150.11 50.66 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.857 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.02 159.34 15.9 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.007 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 128.31 144.39 5.83 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.494 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -53.57 96.9 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.396 0 C-N-CA 122.505 2.137 . . . . 0.0 112.218 179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.39 27.25 3.96 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.466 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -113.91 143.93 43.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.84 0.352 . . . . 0.0 110.852 179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -108.53 154.05 22.49 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.139 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.463 ' CA ' HG22 ' A' ' 316' ' ' ILE . 3.6 m-85 -106.08 114.94 29.37 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.781 -179.964 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.496 HG12 ' N ' ' A' ' 326' ' ' THR . 26.9 t -121.28 159.52 23.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.045 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.496 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -145.03 156.58 44.02 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.894 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.5 mp -140.71 136.4 35.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.216 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.452 -179.945 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.6 mmtp . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.84 0.353 . . . . 0.0 110.989 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.04 104.71 3.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.813 -179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.0 mm -94.62 160.11 2.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.174 -179.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.52 79.81 1.8 Allowed 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.304 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.543 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.3 pt -117.26 119.81 63.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.925 -0.579 . . . . 0.0 111.352 -179.567 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 3.4 mp0 -109.42 143.16 39.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.918 179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.5 134.6 52.21 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.893 -179.969 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 135.63 160.54 8.95 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.487 -179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -53.32 115.85 2.57 Favored 'Trans proline' 0 C--N 1.343 0.266 0 C-N-CA 122.585 2.19 . . . . 0.0 112.202 179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 86.73 27.62 28.81 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.488 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -114.67 117.58 31.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.839 0.352 . . . . 0.0 110.924 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.29 169.99 10.64 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.157 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.543 ' HB3' HG22 ' A' ' 316' ' ' ILE . 35.8 m-85 -117.61 135.37 54.02 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.842 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.488 HG12 ' N ' ' A' ' 326' ' ' THR . 19.2 t -140.23 159.61 25.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.043 179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.488 ' N ' HG12 ' A' ' 325' ' ' VAL . 16.5 p -141.79 133.63 27.27 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.971 -179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.6 mt -128.0 143.15 41.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.25 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.431 179.966 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.1 mmmp? . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.862 0.363 . . . . 0.0 110.95 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . 0.776 ' O ' HD13 ' A' ' 314' ' ' ILE . 0.4 OUTLIER -148.23 138.98 23.0 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.762 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 313' ' ' SER . 2.2 mm -131.69 160.12 42.6 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 120.948 0.404 . . . . 0.0 111.194 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 11.6 tpp180 -134.53 79.95 1.83 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.417 179.356 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.628 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -116.5 126.19 73.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.359 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -150.0 141.1 23.02 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.87 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 3.3 ptm180 -89.87 166.6 13.42 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.992 -179.94 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 130.92 144.25 5.44 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.454 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -53.57 98.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.341 0 C-N-CA 122.536 2.157 . . . . 0.0 112.256 -179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 104.82 28.57 5.59 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.597 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 3.3 mmp_? -112.33 125.18 53.9 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.864 0.364 . . . . 0.0 110.92 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -104.63 155.34 18.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.043 179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.628 ' CD1' HG22 ' A' ' 316' ' ' ILE . 41.6 m-85 -96.33 138.62 33.66 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.883 -179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.46 HG12 ' N ' ' A' ' 326' ' ' THR . 5.9 t -142.54 162.26 18.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.003 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 314' ' ' ILE . 0.7 OUTLIER -149.42 151.87 34.75 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.947 0.403 . . . . 0.0 110.936 179.878 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.461 HG23 ' HB2' ' A' ' 313' ' ' SER . 3.9 tt -136.45 147.57 27.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.987 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 -179.982 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.9 0.381 . . . . 0.0 110.929 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -136.62 107.12 6.49 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.684 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.415 HG22 ' N ' ' A' ' 315' ' ' ARG . 5.4 mm -90.01 160.08 2.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.143 0.497 . . . . 0.0 111.374 -179.779 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.415 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -140.93 79.64 1.71 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.837 178.821 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.673 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.8 pt -113.01 120.65 63.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.417 -179.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.74 134.69 51.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.828 179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 23.5 mtm180 -97.8 165.32 12.0 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.975 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 102.37 146.46 17.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.327 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -53.13 122.9 11.96 Favored 'Trans proline' 0 C--N 1.345 0.391 0 C-N-CA 122.508 2.139 . . . . 0.0 112.234 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 102.3 -19.14 49.54 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.646 -179.93 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 8.7 mpt_? -89.9 126.67 35.8 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 120.845 0.355 . . . . 0.0 110.993 -179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -94.98 169.98 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.008 180.0 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.673 ' HB3' HG22 ' A' ' 316' ' ' ILE . 40.4 m-85 -108.07 135.59 49.18 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.946 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.48 HG12 ' N ' ' A' ' 326' ' ' THR . 17.9 t -132.44 160.16 42.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.09 -0.504 . . . . 0.0 111.047 179.996 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.48 ' N ' HG12 ' A' ' 325' ' ' VAL . 21.0 p -148.14 119.67 7.96 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.97 179.924 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.1 mp -117.58 149.03 19.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.128 179.974 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.257 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.555 -179.98 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.0 mmtt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.77 0.319 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -133.69 119.7 19.67 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.722 179.873 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 1.051 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -111.64 160.21 11.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.048 0.451 . . . . 0.0 111.472 -179.885 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.741 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -139.76 79.64 1.73 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.939 179.067 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.567 HG22 ' CG ' ' A' ' 324' ' ' PHE . 6.7 pt -119.4 120.0 62.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.498 -179.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -131.22 160.06 35.95 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.691 179.959 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.85 160.38 17.43 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.396 -0.366 . . . . 0.0 111.0 -179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 120.67 148.03 7.94 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.84 -0.695 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.13 101.52 0.06 OUTLIER 'Trans proline' 0 C--N 1.344 0.318 0 C-N-CA 122.627 2.218 . . . . 0.0 112.319 179.983 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 112.0 22.89 5.77 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 0.0 112.6 -179.989 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.78 141.19 46.86 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.763 0.316 . . . . 0.0 110.907 179.916 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -120.98 154.82 35.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.065 -179.968 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.567 ' CG ' HG22 ' A' ' 316' ' ' ILE . 3.2 m-85 -105.15 109.89 22.06 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.652 -179.954 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.741 HG23 ' HB2' ' A' ' 315' ' ' ARG . 2.4 m -123.0 166.78 17.39 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.126 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 1.051 HG22 HG23 ' A' ' 314' ' ' ILE . 34.6 p -143.97 125.1 14.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.088 -0.505 . . . . 0.0 110.911 179.92 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.478 HG22 ' N ' ' A' ' 328' ' ' GLY . 8.0 mt -116.65 158.22 17.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.029 -179.866 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . 0.478 ' N ' HG22 ' A' ' 327' ' ' ILE . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.532 -179.983 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 13.2 mmmt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.805 0.336 . . . . 0.0 110.944 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 47.6 t -150.01 107.68 3.67 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.868 179.933 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.43 HG23 HG22 ' A' ' 326' ' ' THR . 5.1 mm -104.84 160.13 5.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.019 0.438 . . . . 0.0 111.48 -179.844 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.423 ' N ' HG22 ' A' ' 314' ' ' ILE . 0.0 OUTLIER -141.63 79.58 1.69 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.932 178.895 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.412 HG22 ' HB3' ' A' ' 324' ' ' PHE . 5.4 pt -119.73 126.34 75.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.456 -179.319 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -123.65 153.21 41.08 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.844 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 13.5 ptp180 -93.61 151.2 19.83 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.954 -179.876 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 152.28 157.76 8.12 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.424 -179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -60.68 -25.6 81.25 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.623 2.215 . . . . 0.0 112.247 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -128.99 28.05 4.19 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.472 179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -96.07 128.31 42.86 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.81 0.338 . . . . 0.0 110.869 179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.87 169.98 10.46 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.127 179.957 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.412 ' HB3' HG22 ' A' ' 316' ' ' ILE . 19.5 m-85 -115.84 125.47 52.71 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.922 -179.948 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.6 t -121.75 153.07 25.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.034 -179.987 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.43 HG22 HG23 ' A' ' 314' ' ' ILE . 15.9 p -150.08 126.48 10.8 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.019 -179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 4.1 mt -127.94 145.58 34.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.936 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.254 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.516 179.938 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 4.4 mmpt? . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.834 0.35 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 9.4 m -149.98 101.01 2.99 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.696 179.876 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.458 HG23 HG22 ' A' ' 326' ' ' THR . 4.6 mm -92.53 160.13 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 121.112 0.482 . . . . 0.0 111.468 -179.715 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 27.0 mtp180 -141.31 79.66 1.7 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.901 178.87 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.449 HG22 ' HA ' ' A' ' 324' ' ' PHE . 4.4 pt -117.61 134.28 61.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.527 -179.249 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -135.54 156.07 49.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.696 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -107.69 155.72 19.86 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.026 -179.898 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 131.83 158.65 9.13 Favored Glycine 0 N--CA 1.452 -0.242 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.529 179.921 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_exo -49.82 121.15 6.89 Favored 'Trans proline' 0 C--N 1.345 0.376 0 C-N-CA 122.551 2.167 . . . . 0.0 112.203 179.862 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 77.41 31.45 51.09 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.623 -0.798 . . . . 0.0 112.278 -179.646 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.79 145.59 25.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.87 0.367 . . . . 0.0 111.06 -179.847 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -129.45 153.9 47.49 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.936 179.936 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.449 ' HA ' HG22 ' A' ' 316' ' ' ILE . 21.4 m-85 -95.9 131.16 42.53 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.003 -179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . . . . . . . . . 21.5 t -123.58 151.87 28.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.018 179.917 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.458 HG22 HG23 ' A' ' 314' ' ' ILE . 20.7 p -148.93 130.3 14.71 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 30.6 mt -128.26 144.08 38.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.155 -179.966 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.416 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.5 -179.99 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 20.3 mmtt . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.872 0.368 . . . . 0.0 111.061 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 32.3 p -137.89 112.39 8.76 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.738 179.883 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 1.8 mm -104.08 160.07 4.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 121.027 0.441 . . . . 0.0 111.312 -179.817 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.715 ' HB2' HG23 ' A' ' 325' ' ' VAL . 0.2 OUTLIER -135.04 79.79 1.81 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.093 179.219 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.521 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.8 pt -111.22 132.58 59.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.972 -0.558 . . . . 0.0 111.446 -179.558 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -149.95 131.74 15.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.7 179.89 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.5 mtm180 -92.2 147.05 23.23 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.979 -179.945 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.31 159.32 8.06 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.408 -179.967 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_exo -52.07 110.76 0.48 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.588 2.192 . . . . 0.0 112.269 -179.978 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 80.07 37.01 23.18 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.512 179.988 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 12.3 mmt180 -115.47 110.11 18.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.829 0.347 . . . . 0.0 110.928 179.993 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.95 164.88 14.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.062 -179.932 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.521 ' CD1' HG22 ' A' ' 316' ' ' ILE . 25.2 m-85 -110.36 110.02 20.66 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.021 -179.958 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.715 HG23 ' HB2' ' A' ' 315' ' ' ARG . 3.5 m -113.14 167.48 6.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.066 179.97 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . . . . . . . . . 1.9 t -150.09 158.08 43.79 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.948 179.93 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.3 mp -139.16 139.2 40.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.096 -179.994 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.358 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.472 -179.966 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 5.0 mmtt . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.82 0.343 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 1.3 m -150.13 117.52 6.08 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.77 179.923 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.6 mm -104.79 160.21 5.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.038 0.447 . . . . 0.0 111.292 -179.87 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 2.6 mmp_? -136.63 79.73 1.78 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.839 -0.618 . . . . 0.0 110.22 179.274 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.529 HG22 ' HB3' ' A' ' 324' ' ' PHE . 2.5 pt -113.57 118.02 57.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.949 -0.569 . . . . 0.0 111.419 -179.515 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -129.42 133.79 47.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.824 179.897 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 11.1 mtp180 -95.58 154.27 17.29 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.952 -179.965 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 151.18 169.57 17.05 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.491 -179.993 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -67.16 95.83 0.38 Allowed 'Trans proline' 0 C--N 1.344 0.301 0 C-N-CA 122.552 2.168 . . . . 0.0 112.28 179.948 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 96.47 27.26 10.01 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.459 179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 20.7 mtt180 -102.78 145.64 29.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.763 0.316 . . . . 0.0 110.924 179.98 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -111.95 169.95 8.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.152 179.972 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.529 ' HB3' HG22 ' A' ' 316' ' ' ILE . 25.5 m-85 -111.86 110.99 21.63 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.941 179.956 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.486 HG12 ' N ' ' A' ' 326' ' ' THR . 19.8 t -108.67 159.61 7.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.14 179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.486 ' N ' HG12 ' A' ' 325' ' ' VAL . 1.5 t -147.88 156.09 42.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.855 179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 25.5 mt -139.39 147.91 23.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.17 179.943 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.33 0 C-N-CA 120.67 -0.776 . . . . 0.0 112.481 -179.959 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 6.2 mmmt . . . . . 0 N--CA 1.458 -0.066 0 CA-C-O 120.842 0.353 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -150.11 128.41 12.1 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.664 179.991 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.509 HG23 ' HB ' ' A' ' 326' ' ' THR . 2.4 mm -118.5 160.23 18.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.993 0.425 . . . . 0.0 111.323 -179.777 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -135.95 79.8 1.79 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.197 179.197 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.9 pt -113.45 129.17 69.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.365 -179.491 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -129.87 153.84 47.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.771 -179.973 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 2.0 mmt180 -93.28 147.59 22.78 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.927 179.972 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 143.71 154.06 6.04 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.498 179.966 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_exo -51.86 -55.22 4.12 Favored 'Trans proline' 0 C--N 1.344 0.32 0 C-N-CA 122.57 2.18 . . . . 0.0 112.32 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -96.56 27.45 17.47 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.516 -179.997 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -97.64 110.82 23.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.882 0.372 . . . . 0.0 110.882 -179.999 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -89.94 163.66 14.88 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.016 179.921 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.718 ' CD1' HG22 ' A' ' 316' ' ' ILE . 24.7 m-85 -104.0 145.53 30.02 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 -179.977 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.49 HG12 ' N ' ' A' ' 326' ' ' THR . 20.2 t -143.67 159.73 16.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.05 -179.93 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.582 ' C ' HD12 ' A' ' 327' ' ' ILE . 1.2 t -150.04 154.09 37.58 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.952 179.969 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.582 HD12 ' C ' ' A' ' 326' ' ' THR . 3.5 mp -145.73 146.59 19.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.073 -179.998 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.294 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.495 179.97 . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 2.6 mmmt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.86 0.362 . . . . 0.0 111.039 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 49.5 m -137.2 101.59 4.58 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.747 179.856 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 2.4 mm -95.44 160.18 2.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 121.049 0.452 . . . . 0.0 111.382 -179.843 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -134.97 79.9 1.81 Allowed 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.149 179.165 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . . . . . . . . . 1.3 pt -110.84 113.02 43.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.379 -179.461 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 1.4 pp0? -138.37 138.39 38.22 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.667 179.847 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 5.1 ptt180 -90.02 162.64 15.26 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.049 -179.806 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 163.73 164.26 18.47 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.331 179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 67.9 Cg_exo -51.22 103.7 0.07 OUTLIER 'Trans proline' 0 C--N 1.344 0.338 0 C-N-CA 122.553 2.169 . . . . 0.0 112.28 -179.924 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 59.64 49.67 76.01 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.472 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 2.5 mtt-85 -104.91 159.55 15.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.871 0.367 . . . . 0.0 110.921 -179.94 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -115.73 170.03 8.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.071 179.968 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -110.59 144.04 40.08 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.998 -179.998 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.494 HG12 ' N ' ' A' ' 326' ' ' THR . 27.1 t -127.82 159.49 38.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.061 -179.982 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.494 ' N ' HG12 ' A' ' 325' ' ' VAL . 17.2 p -149.04 135.57 19.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.908 179.958 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.59 132.72 67.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.072 179.918 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.381 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.547 -179.996 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 36.0 mmtm . . . . . 0 C--O 1.232 0.172 0 CA-C-O 120.767 0.318 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . 0.603 ' C ' HD13 ' A' ' 314' ' ' ILE . 1.0 OUTLIER -145.4 129.44 17.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.845 179.987 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.998 HG23 HG22 ' A' ' 326' ' ' THR . 2.6 mm -122.5 160.22 25.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 0.0 111.3 -179.931 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -135.99 79.69 1.79 Allowed 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.34 179.311 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.722 HG22 ' CD1' ' A' ' 324' ' ' PHE . 2.3 pt -116.95 130.4 71.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.381 -179.502 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -140.85 150.07 42.79 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.789 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -112.29 123.85 51.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.899 -179.947 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 156.08 162.86 11.7 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.445 179.943 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -52.02 100.63 0.05 OUTLIER 'Trans proline' 0 C--N 1.344 0.315 0 C-N-CA 122.665 2.243 . . . . 0.0 112.323 179.97 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 95.75 28.05 9.86 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.51 179.976 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 14.1 mmp_? -112.22 102.45 10.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.754 0.311 . . . . 0.0 110.899 -179.991 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.85 168.86 11.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.282 -0.417 . . . . 0.0 111.075 -179.984 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.722 ' CD1' HG22 ' A' ' 316' ' ' ILE . 29.4 m-85 -107.73 139.24 42.6 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.942 179.97 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 326' ' ' THR . 21.5 t -144.61 156.1 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.151 -179.991 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.998 HG22 HG23 ' A' ' 314' ' ' ILE . 73.6 p -140.82 135.48 31.46 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.92 179.908 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 3.4 mp -134.63 145.8 31.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.1 179.997 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.463 179.925 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 18.4 mmtm . . . . . 0 C--O 1.232 0.159 0 CA-C-O 120.889 0.376 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -148.19 104.83 3.57 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.786 179.935 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . . . . . . . . . 3.4 mm -92.62 160.14 2.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.213 -179.979 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -136.35 79.84 1.79 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.264 179.234 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.522 HG22 ' HB3' ' A' ' 324' ' ' PHE . 4.6 pt -119.99 125.23 74.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.329 -179.6 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -133.56 158.55 42.86 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.843 -179.969 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -98.86 168.07 10.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.979 179.937 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . 145.34 149.98 5.12 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.514 -179.958 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo -52.43 92.65 0.03 OUTLIER 'Trans proline' 0 C--N 1.343 0.267 0 C-N-CA 122.585 2.19 . . . . 0.0 112.296 179.959 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 82.92 45.56 6.64 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.505 179.942 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 21.4 mmm180 -98.75 138.41 35.95 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.763 0.316 . . . . 0.0 110.9 179.99 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -90.03 161.62 15.75 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.056 -179.978 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.522 ' HB3' HG22 ' A' ' 316' ' ' ILE . 53.5 m-85 -116.67 147.09 42.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.483 HG12 ' N ' ' A' ' 326' ' ' THR . 19.5 t -136.09 159.92 38.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.028 -179.905 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.483 ' N ' HG12 ' A' ' 325' ' ' VAL . 34.9 p -145.32 122.84 11.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.974 179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . 0.557 ' N ' HD12 ' A' ' 327' ' ' ILE . 3.4 mp -119.84 138.16 51.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.06 -179.953 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.35 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.566 179.998 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . . . . . . . . . 1.6 mmmt . . . . . 0 N--CA 1.458 -0.036 0 CA-C-O 120.861 0.363 . . . . 0.0 110.943 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 313' ' ' SER . . . . . . . . . . . . . 10.7 t -149.99 108.91 3.88 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.764 179.944 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 314' ' ' ILE . . . . . 0.627 HG23 HG22 ' A' ' 326' ' ' THR . 2.8 mm -95.86 160.16 2.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.224 -179.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 315' ' ' ARG . . . . . 0.712 ' HB3' HG13 ' A' ' 325' ' ' VAL . 1.7 tpt180 -136.03 79.85 1.79 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.272 179.233 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 316' ' ' ILE . . . . . 0.413 HG22 ' CD1' ' A' ' 324' ' ' PHE . 1.5 pt -112.86 114.13 46.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.874 -0.603 . . . . 0.0 111.26 -179.465 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 317' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -122.33 157.24 32.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.841 179.946 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 318' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -113.22 128.61 56.53 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.941 179.959 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 319' ' ' GLY . . . . . . . . . . . . . . . -179.19 157.79 21.33 Favored Glycine 0 N--CA 1.45 -0.412 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.461 179.987 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 320' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -52.04 93.45 0.03 OUTLIER 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.59 2.193 . . . . 0.0 112.286 179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . 89.4 30.36 14.09 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.476 179.98 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 322' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.01 135.7 33.57 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.828 0.347 . . . . 0.0 110.84 -179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 323' ' ' ALA . . . . . . . . . . . . . . . -96.0 169.87 9.68 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.188 -179.983 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 324' ' ' PHE . . . . . 0.413 ' CD1' HG22 ' A' ' 316' ' ' ILE . 53.1 m-85 -120.89 113.41 20.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 179.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 325' ' ' VAL . . . . . 0.712 HG13 ' HB3' ' A' ' 315' ' ' ARG . 10.6 p -119.05 156.32 21.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.967 179.947 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 326' ' ' THR . . . . . 0.627 HG22 HG23 ' A' ' 314' ' ' ILE . 13.6 p -134.51 147.85 50.41 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.993 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 327' ' ' ILE . . . . . . . . . . . . . 21.9 mt -119.53 137.82 52.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.093 179.978 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 328' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.349 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.455 179.979 . . . . . . . . 0 0 . 1 stop_ save_